| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Pharmacology |
University of California Davis Cancer Center, Sacramento, California, USA
Key Words. Hepatic • Renal • Dysfunction • Chemotherapy • Cancer
Correspondence: Correspondence: Angela M. Davies, M.D., F.R.C.P.C., Hematology/Oncology, University of California Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, California 95817, USA. Telephone: 916-734-3771; Fax: 916-734-7946; e-mail: angela.davies{at}ucdmc.ucdavis.edu
Disclosure: A.M.D. has acted as a consultant for Bristol-Myers Squibb, Allos Therapeutics, CTI Therapeutics, Genentech, Millennium, and Lilly, and has received support from Genentech and Aventis.
There are few prospective data regarding the pharmacokinetics and clinical toxicity of commonly used chemotherapeutics in cancer patients with organ dysfunction. Although increasing numbers of studies are investigating newer chemotherapeutics in patients with liver or kidney dysfunction, most guidelines for dosing, especially for established agents, remain empiric. This review describes the available data (both prospective and case study) evaluating the impact of renal and hepatic dysfunction on toxicity and dosing of commonly used chemotherapeutics and provides a practical summary for their use in this setting.
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |